Pharmacogenomics (PGx) Cancer Panel
A 13-gene pharmacogenomic panel for optimizing cancer chemotherapeutics and supportive care medications including antiemetics, antifungals, fluoropyrimidines, and immunosuppressants, powered by the Helix Exome+® platform.
Turnaround
6-9 days
Requery (SOQO)
≤ 5 minutes
Genes Tested
13
Panel Description
This panel evaluates 13 genes associated with response to cancer chemotherapeutics and associated supportive care medications. These include antiemetics, antifungals, antineoplastics, fluoropyrimidines, immunosuppressants, platelet-stimulating agents, proton pump inhibitors, and uric acid inhibitors. Results from this test may help in predicting treatment efficacy and risk of side effects for these drugs. Any information provided for drugs listed under "Limited Evidence Drug-Gene Associations" is provided for informational use only. For sections titled “Limited Evidence Drug-Gene Associations,” no interpretation of expected drug response is provided due to a lack of sufficient evidence and/or available guidelines.
Order This Test
Contact our clinical team to order this panel or learn more.
Genes Tested
13 genes included in this panel
Ordering Information
Turnaround Time
Typically 6-9 days (standard), Typically ≤ 5 minutes (requery)
Preferred Specimen
BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions
Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
Clinical Description
This panel evaluates 13 genes associated with response to cancer chemotherapeutics and associated supportive care medications. These include antiemetics, antifungals, antineoplastics, fluoropyrimidines, immunosuppressants, platelet-stimulating agents, proton pump inhibitors, and uric acid inhibitors. Results from this test may help in predicting treatment efficacy and risk of side effects for these drugs. Any information provided for drugs listed under "Limited Evidence Drug-Gene Associations" is provided for informational use only. For sections titled “Limited Evidence Drug-Gene Associations,” no interpretation of expected drug response is provided due to a lack of sufficient evidence and/or available guidelines.
Ready to order this test?
Contact our clinical team to order the Pharmacogenomics (PGx) Cancer Panel for your patients.